ReviewClinical kidney journal2025
Hypertension burden in CKD: is nocturnal hypertension the primary culprit?
Review in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Dietary Salt Intake and Hypertension in Chronic Kidney Disease.Electrolyte & blood pressure : E & BP · 2026Review
- Pathophysiology, diagnosis and intervention strategies of nocturnal hypertension.Journal of human hypertension · 2026Review
- Nocturnal hypertension in kidney transplant recipients: epidemiology, pathophysiology, prognostic significance, and management.Clinical kidney journal · 2026Review
- Short-term blood pressure variability assessed by ambulatory blood pressure monitoring as a predictor of subclinical target organ damage.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is a pervasive and progressive complication in chronic kidney disease (CKD) patients, affecting up to 90% of those in advanced stages or on dialysis. A particularly insidious aspect of this condition is nocturnal hypertension, characterized by high blood pressure (BP) during sleep and a blunted or absent nighttime BP dipping-phenomena associated with accelerated CKD progression and increased cardiovascular risk. Despite its strong prognostic significance, nocturnal hypertension remains underdiagnosed due to limited use of ambulatory BP monitoring. This narrative review explores the pathophysiological underpinnings of nocturnal hypertension in CKD, including impaired sodium handling, volume overload, autonomic dysfunction and dysregulation of the renin-angiotensin-aldosterone system. Emerging evidence highlights its associations with left ventricular hypertrophy, proteinuria, endothelial dysfunction and poor renal outcomes, emphasizing the need for comprehensive BP profiling and targeted management strategies. Current therapeutic approaches include lifestyle modifications, diuretics and antihypertensive pharmacotherapy, with growing interest in chronotherapy-the timing of medication administration to align with circadian BP rhythms. However, robust clinical data specifically guiding the treatment of nocturnal hypertension in CKD remain scarce. This review underscores the clinical importance of diagnosing and addressing nocturnal BP abnormalities and advocates for future trials focused on optimizing management strategies for this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.